Pall opens Center of Excellence in Shanghai

19 Dec 2018

The CoE showcases the latest end-to-end technological solutions for biomanufacturing.

Pall Corporation has established a Biotech Integrated Solutions Center of Excellence (CoE) in Shanghai, China. Strategically located in the heart of Shanghai’s renowned life science cluster, the CoE is a new state-of-the-art facility for bioprocess engineering consultancy, technology demonstration, testing and training for China and broader Asia.

Pall opens Center of Excellence in Shanghai

Equipped with advanced bioprocessing equipment and automation platforms, the CoE showcases the latest end-to-end technological solutions for biomanufacturing, including single-use cell culture solutions, cell clarification using acoustic wave technology, chromatography using automated packing techniques, viral clearance, tangential flow filtration and mixer/container modules. It is designed to lead Pall’s customers through the sequential stages of process flow and will serve as a proving ground for new technologies, as well as a training facility for Pall customers and Pall employees.

“As the biopharmaceutical industry moves from traditional batch or single-use processing to continuous bioprocessing solutions, Pall is poised to help customers reduce process development and production costs and drive significant improvements in efficacy and productivity,” President of Pall Corporation, Jennifer Honeycutt, explained.

“Our investment in the new Shanghai CoE is designed to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, depending upon where customers are in their journey. The goal is to provide technology solutions that meet their current needs, while offering some of the most progressive technological solutions for the future,” added Honeycutt. “By opening this state-of-the-art facility, we hope to unlock new opportunities for our customers based in China, and for any global customers looking to enter or expand their operations in the Asia Pacific region.”

Pall Biotech has invested heavily in a growing network of CoE facilities worldwide to support its global biopharmaceutical customer base. Three CoE facilities currently exist in Portsmouth (UK), Westborough (USA), and Shanghai (China), with planning for a new European facility in process.

Read More

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
Lilly to bag Loxo Oncology for $8 billion

Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Read more 
Catalent to double its commercial biomanufacturing capacity

Catalent to double its commercial biomanufacturing capacity

7 Jan 2019

The $200-million expansion will support customers’ development programs and commercial launches.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
Cambrex completes acquisition of Avista Pharma Solutions

Cambrex completes acquisition of Avista Pharma Solutions

2 Jan 2019

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

Read more 
Novartis offers to acquire CellforCure

Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Read more 
BMS receives offer from Taisho to purchase UPSA

BMS receives offer from Taisho to purchase UPSA

30 Dec 2018

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Read more 
Recipharm to potentially end operations in Ashton-under-Lyne facility

Recipharm to potentially end operations in Ashton-under-Lyne facility

24 Dec 2018

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more